In 2024, Evaluate projected that the top 10 expected launches were expected to generate $15.2 billion in sales by 2028. This year’s list is projected to generate nearly double that at $29 billion in annual sales by the end of the decade. This list is the highest projected list in the last five years. One of the primary reasons for the increased figures is a new cystic fibrosis offering from Vertex Pharmaceuticals that tops the list.
Click here to read the entire article and view the list.